세계의 마이크로캐리어 시장 : 제품별, 용도별, 최종사용자별, 예측(2024-2032년)

Global Microcarrier Market Size will grow at 9.5% CAGR during 2024-2032, driven by Increasing adoption of microcarriers in cell culture processes, advancements in R&D activities, expanding applications beyond traditional cell culture processes, and rising demand for cell-based therapies and biologics.

Urbanization leads to an increase in demand for healthcare services, including advanced medical treatments and therapies that utilize cell-based technologies. According to the World Bank, currently, at least half of the global population resides in urban areas. As per data, by 2045, the world's urban population will surge by 1.5 times to reach 6 billion. As more people move to urban areas, there is a greater need for biopharmaceutical products, regenerative medicine, and personalized therapies to address the healthcare needs of densely populated urban communities. This trend drives the demand for microcarriers, which are essential in the production of cell-based therapies, vaccines, and biologics used to treat various diseases prevalent in urban settings.

The Microcarrier Market is classified based on equipment, product, application, end-user, and region.

The equipment segment will grow substantially by 2032, as the availability of advanced equipment and technologies for microcarrier-based cell culture systems enhances process efficiency, scalability, and reproducibility. Equipment such as bioreactors, spinner flasks, and cell culture vessels support the cultivation of cells on microcarriers, facilitating the production of large quantities of cells for various applications. As biopharmaceutical and biotechnology companies invest in state-of-the-art equipment to optimize cell culture processes, further segment growth is anticipated.

The regenerative medicine segment will capture a decent Microcarrier Market share by 2032, as microcarriers are used in regenerative medicine applications, including tissue engineering, cell therapy, and organ regeneration. These biocompatible scaffolds provide a three-dimensional microenvironment conducive to cell attachment, proliferation, and differentiation, enabling the development of advanced regenerative therapies. With the growing focus on personalized medicine and the treatment of chronic diseases, the demand for microcarriers in regenerative medicine applications is expected to further soar, driving market expansion.

Asia Pacific Microcarriers Industry will register commendable growth through 2032, driven by increasing investment in biopharmaceutical research and development, expanding biotechnology industry, and rising demand for cell-based therapies. Countries like China, India, South Korea, and Japan are at the forefront of biopharmaceutical innovation and regenerative medicine research, contributing to the growth. Additionally, supportive government initiatives, a favorable regulatory environment, and collaborations between academia and industry further propel market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculation
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing cases of cancer and chronic diseases
    • 3.2.1.2 Advancements in cell culture technologies
    • 3.2.1.3 Rising investments in biotechnology and life sciences
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Biocompatibility and immunogenicity concerns
    • 3.2.2.2 High cost associated with serum-free media
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
  • 5.2.1 Microcarrier beads
    • 5.2.1.1 Collagen coated beads
    • 5.2.1.2 Cationic beads
    • 5.2.1.3 Protein coated beads
    • 5.2.1.4 Untreated beads
    • 5.2.1.5 Other microcarrier beads
  • 5.2.2 Media
    • 5.2.2.1 Serum based media
    • 5.2.2.2 Serum-free media
    • 5.2.2.3 Other media
  • 5.2.3 Reagents
  • 5.2.4 Other consumables
• 5.3 Equipment
  • 5.3.1 Bioreactor
    • 5.3.1.1 Single-use bioreactor
    • 5.3.1.2 Stainless steel bioreactor
  • 5.3.2 Culture vessel
  • 5.3.3 Cell counter
  • 5.3.4 Filtration system
  • 5.3.5 Other equipment

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Biopharmaceutical production
  • 6.2.1 Vaccine production
  • 6.2.2 Therapeutics production
• 6.3 Regenerative medicine
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biotechnology companies
• 7.3 CROs & CMOs
• 7.4 Academic & research institutes
• 7.5 Cell banks

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Bio-Rad Laboratories, Inc.
• 9.2 Corning Incorporated
• 9.3 Cytiva
• 9.4 denovoMATRIX GmbH
• 9.5 Eppendorf AG
• 9.6 Fujiform Holdings Corporation
• 9.7 Lonza Group AG
• 9.8 Merck KGaA
• 9.9 Sartorious AG
• 9.10 Thermo Fisher Scientific Inc.